CNBC April 26, 2024
Key Points
– The Food and Drug Administration approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to win clearance in the U.S.
– The agency greenlighted the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B.
– Pfizer said the treatment will be available by prescription to eligible patients this quarter and has a hefty $3.5 million price tag before insurance and other rebates.
The Food and Drug Administration on Friday announced that the agency approved Pfizer‘s treatment for a rare genetic bleeding disorder, making it the company’s first gene therapy to win clearance in the U.S.
The agency greenlighted the drug, which...
Today's Sponsors
Today's Sponsor